Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services
News Jul 09, 2015
To be established over the next few months, the new, hand-picked Board will bring together the most highly experienced scientists with extensive drug discovery backgrounds in the fields of Chronic Pain and CNS research, extending Cellectricon’s expertise in these areas.
“Cellectricon is assembling a first-class team of scientists and engineers - all focused on the challenging task of developing enhanced assay technologies for early stage Pain and CNS drug discovery” said Dr Johnson. “I am pleased to join its Scientific Advisory Board and look forward to helping the company as it pursues this mission.”
Edwin Johnson has over 20 years’ experience in CNS discovery and development, especially in the areas of neuroscience. With over 50 peer-reviewed publications and 10 patents, he has been extensively involved in numerous drug discovery programmes. In addition, he has also headed up teams working on drugs for the treatment of cognitive disorders, Parkinson’s disease and depression, taking them through clinical development. Since 2012, Edwin has headed the Stockholm Brain Institute and is the CNS lead at Karolinska Institutet Innovations.
“In the past 12 months we have gained significant traction with our Discovery Services offering based on our proprietary Cellaxess® Elektra phenotypic assay platform and expert scientific staff”, said Cellectricon’s CEO, David Burns. “In order to further add value, we are expanding our Discovery Services offering to include a range of complementary cell-based assays that encompass profiling further along the drug discovery process. We are very pleased to welcome Dr Johnson to our newly-formed Scientific Advisory Board, as he will provide valuable domain knowledge that will aid the development of our proprietary Discovery Services for our clients.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE